코로나바이러스감염증-19(COVID-19)는 SARS-CoV-2에 의해 발병된다. 지금까지 인간에게 감염되는 7 가지 종류의 코로나 바이러스가 보고되었다. 그 중, HCoV-229E, HCoV-OC43, HCoV-NL63, 그리고 HCoV-HKU1 등 4...

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107014255
2020
English
KCI등재
학술저널
731-741(11쪽)
0
0
상세조회0
다운로드코로나바이러스감염증-19(COVID-19)는 SARS-CoV-2에 의해 발병된다. 지금까지 인간에게 감염되는 7 가지 종류의 코로나 바이러스가 보고되었다. 그 중, HCoV-229E, HCoV-OC43, HCoV-NL63, 그리고 HCoV-HKU1 등 4...
코로나바이러스감염증-19(COVID-19)는 SARS-CoV-2에 의해 발병된다. 지금까지 인간에게 감염되는 7 가지 종류의 코로나 바이러스가 보고되었다. 그 중, HCoV-229E, HCoV-OC43, HCoV-NL63, 그리고 HCoV-HKU1 등 4종류의 코로나바이러스는 감기와 같은 단순 호흡기 질환을 유발한다고 보고되었다. 반면, SARS-CoV는 2002년에, MERS-CoV는 2012년에 각각 대유행을 일으킨 바 있다. 가장 최근에는 2019년 12월 중국 우한에서 처음 보고된 SARS-CoV-2가 전세계적인 대유행의 원인이 되고 있다. 이러한 SARS-CoV-2를 진단하고, 치료하고, 예방하기 위해서는 신속 정확한 진단키트, 치료제, 그리고 안전한 백신의 개발의 필수적으로 요구된다. 이러한 강력한 도구들을 개발하기 위해서는 SARS-CoV-2의 표현형, 유전자형, 그리고 생활주기 등의 연구가 선행되어야 한다. SARSCoV-2의 진단기술은 현재 크게 두가지의 큰 분야인 분자진단과 면역혈청학적 진단으로 구분할 수 있다. 분자진단의 경우 SARS-CoV-2의 유전체를 대상으로 하며, 면역혈청학적 진단은 SARS-CoV-2의 항원 단백질 혹은 SARSCoV-2에 대한 항체를 대상으로 한다. 본 총설에서는 SARS-CoV-2의 표현형, 유전체 구조, 그리고 유전자 발현에 대해서 정리하고, SARS-CoV-2에 대한 다양한 진단 기술 등에 대한 기초지식을 제공하고자 한다.
다국어 초록 (Multilingual Abstract)
Coronavirus disease 19 (COVID-19) is caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome- Coronavirus 2). To date, seven coronaviruses that can infect humans were reported. Among them, infections with four coronavirus strains (HCoV-229E, HCoV-OC43...
Coronavirus disease 19 (COVID-19) is caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome- Coronavirus 2). To date, seven coronaviruses that can infect humans were reported. Among them, infections with four coronavirus strains (HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1) resulted in mild symptoms such as common cold, whereas SARS-CoV and MERS-CoV caused severe symptoms and epidemics in 2002 and 2012, respectively. In the most recent, SARS-CoV-2 was first reported in Wuhan, China in December 2019 and became a notorious cause of the ongoing global pandemics. To diagnose, treat, and prevent COVID-19, the development of rapid and accurate diagnostic tools, specific therapeutic drugs, and safe vaccines essentially are required. In order to develop these powerful tools, it is prerequisite to understand a phenotype, a genotype, and life cycle of SARS-CoV-2. Diagnostic techniques have been developing rapidly around world and many countries take the fast track system to accelerate approval. Approved diagnostic devices are rapidly growing facing to urgent demand to identify carriers. Currently developed commercial diagnostic devices are divided into mainly two categories: molecular assay and serological & immunological assay. Molecular assays begins the reverse transcription step following polymerase chain reaction or isothermal amplification. Immunological assay targets SARS-CoV-2 antigen or anti-SARS-CoV-2 antibody of samples. In this review, we summarize the phenotype, genome structure and gene expression of SARS-CoV-2 and provide the knowledge on various diagnostic techniques for SARS-CoV-2.
참고문헌 (Reference)
1 Ziebuhr, J., "Virusencoded proteinases and proteolytic processing in the Nidovirales" 81 : 853-879, 2000
2 Jin, Y., "Virology, epidemiology, pathogenesis, and control of COVID-19" 12 : 372-, 2020
3 Li, H., "Updated approaches against SARS-CoV-2" 64 : e00483-20, 2020
4 Jacofsky, D., "Understanding antibody testing for COVID-19" 35 : S74-, 2020
5 Du, L., "The spike protein of SARS-CoV--a target for vaccine and therapeutic development" 7 : 226-236, 2009
6 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, "The species severe acute respiratory syndrome-related coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2" 5 : 536-544, 2020
7 Masters, P. S., "The molecular biology of coronaviruses" 66 : 193-292, 2006
8 Kim, D., "The architecture of SARS-CoV-2 transcriptome" 181 : 914-921, 2020
9 Chang, C. K., "The SARS coronavirus nucleocapsid protein--forms and functions" 103 : 39-50, 2014
10 Whitman, J. D., "Test performance evaluation of SARS-CoV-2serological assays"
1 Ziebuhr, J., "Virusencoded proteinases and proteolytic processing in the Nidovirales" 81 : 853-879, 2000
2 Jin, Y., "Virology, epidemiology, pathogenesis, and control of COVID-19" 12 : 372-, 2020
3 Li, H., "Updated approaches against SARS-CoV-2" 64 : e00483-20, 2020
4 Jacofsky, D., "Understanding antibody testing for COVID-19" 35 : S74-, 2020
5 Du, L., "The spike protein of SARS-CoV--a target for vaccine and therapeutic development" 7 : 226-236, 2009
6 Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, "The species severe acute respiratory syndrome-related coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2" 5 : 536-544, 2020
7 Masters, P. S., "The molecular biology of coronaviruses" 66 : 193-292, 2006
8 Kim, D., "The architecture of SARS-CoV-2 transcriptome" 181 : 914-921, 2020
9 Chang, C. K., "The SARS coronavirus nucleocapsid protein--forms and functions" 103 : 39-50, 2014
10 Whitman, J. D., "Test performance evaluation of SARS-CoV-2serological assays"
11 Wang, Q., "Structural and functional Basis of SARS-CoV-2 entry by using human ACE2" 181 : 894-904, 2020
12 Tseng, Y. T., "Self-assembly of severe acute respiratory syndrome coronavirus membrane protein" 285 : 12862-12872, 2010
13 Amanat, F., "SARS-CoV-2 vaccines : status report" 52 : 583-589, 2020
14 Özçürümez, M. K., "SARS-CoV-2 antibody testing-questions to be asked" 146 : 35-43, 2020
15 Shen, M., "Recent advances and perspectives of nucleic acid detection for coronavirus" 10 : 97-101, 2020
16 Bustin, S. A., "RT-qPCR testing of SARS-CoV-2 : a primer" 21 : 3004-, 2020
17 Huang, W. E., "RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2" 13 : 950-961, 2020
18 Korea Ministry of Food and Drug Safety., "Public Report for Emergency-use-authorization"
19 APHL, "Public Health Considerations: Serologic Testing for COVID-19"
20 FDA, "Policy for diagnostic tests for coronavirus disease-2019during the public health emergency"
21 Golfetto, L., "PCR-RFLP assay as an option for primary HPV test" 51 : e7098-, 2018
22 Cui, J., "Origin and evolution of pathogenic coronaviruses" 17 : 181-192, 2019
23 Huang, H. S., "Multiplex PCR system for the rapid diagnosis of respiratory virus infection : systematic review and meta-analysis" 24 : 1055-1063, 2017
24 WHO, "Molecular assays to diagnose COVID-19: Summary table of available protocols"
25 Kilic, T., "Molecular and immunological diagnostic tests of COVID-19 : current status and challenges" 23 : 101406-, 2020
26 Korea Ministry of Food and Drug Safety, "List of COVID-19in-vitro diagnostic devices approved by MFDS (`20.8.6)"
27 FDA, "List of COVID-19 in-vitro diagnostic devices approved by FDA"
28 WHO, "Laboratory testing strategy recommendations for COVID-19: interim guidance"
29 Tang, Y. W., "Laboratory diagnosis of COVID-19 : current issues and challenges" 26 : e00512-520, 2020
30 Zaki, A. M., "Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia" 367 : 1814-1820, 2012
31 Sethuraman, N., "Interpreting diagnostic tests for SARS-CoV-2" 323 : 2249-2251, 2020
32 Ashour, H. M., "Insights into the recent 2019 novel coronavirus(SARS-CoV-2)in light of past human coronavirus outbreaks" 9 : 186-, 2020
33 Hussain, S., "Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus" 79 : 5288-5295, 2005
34 Drosten, C., "Identification of a novel coronavirus in patients with severe acute respiratory syndrome" 348 : 1967-1976, 2003
35 van der Hoek, L., "Human coronaviruses: what do they cause?" 12 : 651-658, 2007
36 Leila Mousavizadeh, "Genotype and phenotype of COVID-19: Their roles in pathogenesis" Elsevier BV 2020
37 Lu, R., "Genomic characterisation and epidemiology of 2019 novel coronavirus : implications for virus origins and receptor binding" 395 : 565-574, 2020
38 Xu, Y., "Fluorescent probe-based lateral flow assay for multiplex nucleic acid detection" 86 : 5611-5614, 2014
39 Su, S., "Epidemiology, genetic recombination, and pathogenesis of coronaviruses" 24 : 490-502, 2016
40 Wang, S., "Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2" 136 : 8-15, 2008
41 Pachetti, M., "Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant" 18 : 179-, 2020
42 Woo, P. C., "Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus" 86 : 3995-4008, 2012
43 Li, Z., "Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis" 92 : 1-3, 2020
44 Hou, H., "Detection of IgM and IgG antibodies in patients with coronavirus disease 2019" 9 : e01136-, 2019
45 Corman, V. M., "Detection of 2019 novel coronavirus(2019-nCoV)by real-time RTPCR" 25 : 2000045-, 2020
46 안대균, "Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19)" 한국미생물·생명공학회 30 (30): 313-324, 2020
47 WHO, "Country & Technical Guidance - Coronavirus disease (COVID-19)"
48 Perlman, S., "Coronaviruses post-SARS : update on replication and pathogenesis" 7 : 439-450, 2009
49 Fehr, A. R., "Coronaviruses : an overview of their replication and pathogenesis" 1282 : 1-23, 2015
50 Li, G., "Coronavirus infections and immune responses" 92 : 424-432, 2020
51 Brian, D. A., "Coronavirus genome structure and replication" 287 : 1-30, 2005
52 Schoeman, D., "Coronavirus envelope protein : current knowledge" 16 : 69-, 2019
53 Woo, P. C., "Coronavirus diversity, phylogeny and interspecies jumping" 234 : 1117-1127, 2009
54 Lai, M. M., "Coronavirus : organization, replication and expression of genome" 44 : 303-333, 1990
55 Sola, I., "Continuous and discontinuous RNA synthesis in coronaviruses" 2 : 265-288, 2015
56 Tai, W., "Characterization of the receptor-binding domain(RBD)of 2019 novel coronavirus : implication for development of RBD protein as a viral attachment inhibitor and vaccine" 17 : 613-620, 2020
57 Younes, N., "Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2" 12 : 582-, 2020
58 Broughton, J. P., "CRISPR-Cas12-based detection of SARS-CoV-2" 38 : 870-874, 2020
59 Carter, L. J., "Assay techniques and test development for COVID-19 diagnosis" 6 : 591-605, 2020
60 Zhao, J., "Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019" ciaa344-, 2020
61 CDC, "Antibody Testing Interim Guidelines"
62 Mukama, O., "An ultrasensitive and specific point-of-care CRISPR/Cas12 based lateral flow biosensor for the rapid detection of nucleic acids" 159 : 112143-, 2020
63 Zhou, P., "A pneumonia outbreak associated with a new coronavirus of probable bat origin" 579 : 270-273, 2020
64 Saberi, A., "A planarian nidovirus expands the limits of RNA genome size" 14 : e1007314-, 2018
65 Lu, R., "A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2" 21 : 2826-, 2020
66 Zhu, N., "A novel coronavirus from patients with pneumonia in China, 2019" 382 : 727-733, 2019
67 Arbely, E., "A highly unusual palindromic transmembrane helical hairpin formed by SARS coronavirus E protein" 341 : 769-779, 2004
68 CDC, "2019-Novel Coronavirus (2019-nCoV) Real-Time RTPCR Diagnostic Panel"
A Novel PHKA1 Mutation in a Patient with Glycogen Storage Disease Type IXD
학술지 이력
| 연월일 | 이력구분 | 이력상세 | 등재구분 |
|---|---|---|---|
| 2027 | 평가 | 재인증평가 신청대상 (재인증) | |
| 2021-01-01 | 등재 | 등재학술지 유지 (재인증) | ![]() |
| 2018-01-01 | 등재 | 등재학술지 유지 (등재유지) | ![]() |
| 2015-01-01 | 등재 | 등재학술지 유지 (등재유지) | ![]() |
| 2011-08-03 | 학술지명변경 | 외국어명 : Korean Journal of Life Science -> Journal of Life Science | ![]() |
| 2011-01-01 | 등재 | 등재학술지 유지 (등재유지) | ![]() |
| 2009-01-01 | 등재 | 등재학술지 유지 (등재유지) | ![]() |
| 2007-01-01 | 등재 | 등재학술지 유지 (등재유지) | ![]() |
| 2004-01-01 | 등재 | 등재학술지 선정 (등재후보2차) | ![]() |
| 2003-01-01 | 등재 | 등재후보 1차 PASS (등재후보1차) | ![]() |
| 2001-07-01 | 등재 | 등재후보학술지 선정 (신규평가) | ![]() |
학술지 인용정보
| 기준연도 | WOS-KCI 통합IF(2년) | KCIF(2년) | KCIF(3년) |
|---|---|---|---|
| 2016 | 0.37 | 0.37 | 0.42 |
| KCIF(4년) | KCIF(5년) | 중심성지수(3년) | 즉시성지수 |
| 0.43 | 0.43 | 0.774 | 0.09 |